Oncologic PET/MRI, part 1: Tumors of the brain, head and neck, chest, abdomen, and pelvis

Journal of Nuclear Medicine

Volumn 53, Issue 6, 2012, Pages 928-938

  Buchbender, Christian ^a   Heusner, Till A ^a   Lauenstein, Thomas C ^b   Bockisch, Andreas ^b   Antoch, Gerald ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Cancer; MRI; Oncology; PET; PET MRI

Indexed keywords

ANTINEOPLASTIC AGENT;

ABDOMINAL TUMOR; BRAIN METASTASIS; BRAIN TUMOR; BREAST CARCINOMA; CANCER STAGING; CHEMORADIOTHERAPY; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; GLIOMA; HEAD AND NECK CARCINOMA; HEAD AND NECK TUMOR; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LUNG TUMOR; LYMPH NODE METASTASIS; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PELVIS TUMOR; POSITRON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RELIABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; THORAX TUMOR; TONGUE CARCINOMA; TREATMENT RESPONSE; WHOLE BODY IMAGING;

ABDOMINAL NEOPLASMS; BRAIN NEOPLASMS; HEAD AND NECK NEOPLASMS; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; NEOPLASMS; PELVIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; THORACIC NEOPLASMS;

EID: 84861848020     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.105338     Document Type: Review

References (80)

1. Edge SB, Byrd DR, Compton CC, et al., eds. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2009.
2. Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004;22:4357-4368. (Pubitemid 41185156)
3. Antoch G, Bockisch A. Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging. 2009;36(suppl 1):S113-S120.
4. Antoch G, Vogt FM, Freudenberg LS, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA. 2003;290:3199-3206. (Pubitemid 38020681)
5. Melcher CL. Scintillation crystals for PET. J Nucl Med. 2000;41:1051-1055. (Pubitemid 30396657)
6. Stoeckli SJ, Steinert H, Pfaltz M, Schmid S. Is there a role for positron emission tomography with 18F-fluorodeoxyglucose in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinoma. Head Neck. 2002;24:345-349. (Pubitemid 34260038)
7. Zhong JH, Gore JC. Studies of restricted diffusion in heterogeneous media containing variations in susceptibility. Magn Reson Med. 1991;19:276-284.
8. Vandecaveye V, De Keyzer F, Vander Poorten V, et al. Head and neck squamous cell carcinoma: value of diffusion-weighted MR imaging for nodal staging. Radiology. 2009;251:134-146.
9. Morita N, Harada M, Otsuka H, Melhem ER, Nishitani H. Clinical application of MR spectroscopy and imaging of brain tumor. Magn Reson Med Sci. 2010;9: 167-175.
10. Poptani H, Gupta RK, Roy R, Pandey R, Jain VK, Chhabra DK. Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. AJNR. 1995;16:1593-1603.
11. Gore JC, Manning HC, Quarles CC, Waddell KW, Yankeelov TE. Magnetic resonance in the era of molecular imaging of cancer. Magn Reson Imaging. 2011;29:587-600.
12. Yokoi K, Kamiya N, Matsuguma H, et al. Detection of brain metastasis in potentially operable non-small cell lung cancer: a comparison of CT and MRI. Chest. 1999;115:714-719. (Pubitemid 29129950)
13. Rohren EM, Provenzale JM, Barboriak DP, Coleman RE. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology. 2003;226:181-187. (Pubitemid 36163927)
14. Krüger S, Mottaghy FM, Buck AK, et al. Brain metastasis in lung cancer: comparison of cerebral MRI and 18F-FDG-PET/CT for diagnosis in the initial staging. Nuklearmedizin. 2011;50:101-106.
15. Kwee SA, Ko JP, Jiang CS, Watters MR, Coel MN. Solitary brain lesions enhancing at MR imaging: evaluation with fluorine 18 fluorocholine PET. Radiology. 2007;244:557-565. (Pubitemid 47080889)
16. Horky LL, Hsiao EM, Weiss SE, Drappatz J, Gerbaudo VH. Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis. J Neurooncol. 2011;103:137-146.
17. 18F-FDG PET in primary diagnosis and staging of patients with thoracic cancer. J Nucl Med. 2002;43:167-172.
18. Schlemmer HP, Pichler BJ, Schmand M, et al. Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology. 2008;248:1028-1035.
19. Boss A, Bisdas S, Kolb A, et al. Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med. 2010;51:1198-1205.
20. Thomson V, Pialat JB, Gay F, et al. Whole-body MRI for metastases screening: a preliminary study using 3D VIBE sequences with automatic subtraction between noncontrast and contrast enhanced images. Am J Clin Oncol. 2008;31:285-292.
21. Schmidt GP, Baur-Melnyk A, Herzog P, et al. High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system. Invest Radiol. 2005;40:743-753. (Pubitemid 41690430)
22. Veit-Haibach P, Luczak C, Wanke I, et al. TNM staging with FDG-PET/CT in patients with primary head and neck cancer. Eur J Nucl Med Mol Imaging. 2007;34:1953-1962. (Pubitemid 350212141)
23. Boss A, Stegger L, Bisdas S, et al. Feasibility of simultaneous PET/MR imaging in the head and upper neck area. Eur Radiol. 2011;21:1439-1446.
24. Nakamoto Y, Tamai K, Saga T, et al. Clinical value of image fusion from MR and PET in patients with head and neck cancer. Mol Imaging Biol. 2009;11:46-53.
25. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of occult primary head and neck cancers: an audit and review of published studies. Clin Oncol (R Coll Radiol). 2012;24:190-195.
26. Liao CT, Wang HM, Huang SF, et al. PET and PET/CT of the neck lymph nodes improves risk prediction in patients with squamous cell carcinoma of the oral cavity. J Nucl Med. 2011;52:180-187.
27. 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med. 2008;49:532-540.
28. Gupta T, Master Z, Kannan S, et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38:2083-2095.
29. Yao M, Smith RB, Graham MM, et al. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys. 2005;63:991-999. (Pubitemid 41505274)
30. Razek AA, Megahed AS, Denewer A, Motamed A, Tawfik A, Nada N. Role of diffusion-weighted magnetic resonance imaging in differentiation between the viable and necrotic parts of head and neck tumors. Acta Radiol. 2008;49:364-370.
31. Liu J, Yang X, Li F, Wang X, Jiang X. Preliminary study of whole-body diffusion-weighted imaging in detecting pulmonary metastatic lesions from clear cell renal cell carcinoma: comparison with CT. Acta Radiol. 2011;52:954-963.
32. Lauenstein TC, Goehde SC, Herborn CU, et al. Whole-body MR imaging: evaluation of patients for metastases. Radiology. 2004;233:139-148. (Pubitemid 39280968)
33. Kuhl C. The current status of breast MR imaging. Part 1. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. Radiology. 2007;244:356-378. (Pubitemid 47080868)
34. Moy L, Noz ME, Maguire GQ Jr, et al. Role of fusion of prone FDG-PET and magnetic resonance imaging of the breasts in the evaluation of breast cancer. Breast J. 2010;16:369-376.
35. Hahn S, Heusner T, Kummel S, et al. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer. Acta Radiol. 2011;52:1009-1014.
36. Uematsu T, Kasami M, Yuen S. Comparison of FDG PET and MRI for evaluating the tumor extent of breast cancer and the impact of FDG PET on the systemic staging and prognosis of patients who are candidates for breast-conserving therapy. Breast Cancer. 2009;16:97-104.
37. Harnan SE, Cooper KL, Meng Y, et al. Magnetic resonance for assessment of axillary lymph node status in early breast cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2011;37:928-936.
38. Heusner TA, Kuemmel S, Hahn S, et al. Diagnostic value of full-dose FDG PET/ CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging. 2009;36:1543-1550.
39. Aukema TS, Straver ME, Peeters MJ, et al. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer. Eur J Cancer. 2010;46:3205-3210.
40. Murakami R, Kumita SI, Yoshida T, et al. FDG-PET/CT in the diagnosis of recurrent breast cancer. Acta Radiol. 2012;53:12-16.
41. Filippi V, Malamitsi J, Vlachou F, et al. The impact of FDG-PET/CT on the management of breast cancer patients with elevated tumor markers and negative or equivocal conventional imaging modalities. Nucl Med Commun. 2011;32:85-90.
42. Avril N, Sassen S, Roylance R. Response to therapy in breast cancer. J Nucl Med. 2009;50(suppl 1):55S-63S.
43. Chen JH, Bahri S, Mehta RS, et al. Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging. Radiology. 2011;261:735-743.
44. Wang XH, Peng WJ, Tan HN, et al. Value of diffusion weighted imaging (DWI) in evaluating early response to neoadjuvant chemotherapy in locally advanced breast cancer [in Chinese]. Zhonghua Zhong Liu Za Zhi. 2010;32:377-381.
45. Ueda S, Tsuda H, Saeki T, et al. Early reduction in standardized uptake value after one cycle of neoadjuvant chemotherapy measured by sequential FDG PET/ CT is an independent predictor of pathological response of primary breast cancer. Breast J. 2010;16:660-662.
46. 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med. 2008;49:1912-1921.
47. 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med. 2010;51:1699-1706.
48. Di Martino M, Marin D, Guerrisi A, et al. Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis. Radiology. 2010;256:806-816.
49. Park G, Kim YK, Kim CS, Yu HC, Hwang SB. Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine. Br J Radiol. 2010;83:1010-1016.
50. Yu JS, Chung JJ, Kim JH, et al. Detection of small intrahepatic metastases of hepatocellular carcinomas using diffusion-weighted imaging: comparison with conventional dynamic MRI. Magn Reson Imaging. 2011;29:985-992.
51. Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med. 1995;36: 1811-1817.
52. Yoon KT, Kim JK, Kim Do Y, et al. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. Oncology. 2007;72(suppl 1):104-110. (Pubitemid 350256673)
53. Akduman EI, Momtahen AJ, Balci NC, Mahajann N, Havlioglu N, Wolverson MK. Comparison between malignant and benign abdominal lymph nodes on diffusion-weighted imaging. Acad Radiol. 2008;15:641-646. (Pubitemid 351509765)
54. Shiomi S, Nishiguchi S, Ishizu H, et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol. 2001;96:1877-1880.
55. Sun L, Guan YS, Pan WM, et al. Metabolic restaging of hepatocellular carcinoma using whole-body F-FDG PET/CT. World J Hepatol. 2009;1:90-97.
56. Bolog N, Pfammatter T, Mullhaupt B, Andreisek G,Weishaupt D. Double-contrast magnetic resonance imaging of hepatocellular carcinoma after transarterial chemoembolization. Abdom Imaging. 2008;33:313-323. (Pubitemid 351537872)
57. Nakanishi M, Chuma M, Hige S, et al. Relationship between diffusion-weighted magnetic resonance imaging and histological tumor grading of hepatocellular carcinoma. Ann Surg Oncol. 2012;19:1302-1309.
58. Pathak S, Jones R, Tang JM, et al. Ablative therapies for colorectal liver metastases: a systematic review. Colorectal Dis. 2011;13:e252-e265.
59. Piscaglia F, Corradi F, Mancini M, et al. Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer. BMC Cancer. 2007;7:171.
60. 18F- fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases. Invest Radiol. 2011;46:548-555.
61. Antoch G, Vogt FM, Veit P, et al. Assessment of liver tissue after radiofrequency ablation: findings with different imaging procedures. J Nucl Med. 2005;46:520-525. (Pubitemid 43093165)
62. Veit P, Antoch G, Stergar H, Bockisch A, Forsting M, Kuehl H. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol. 2006;16:80-87. (Pubitemid 43103572)
63. Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol. 1996;14:700-708. (Pubitemid 26085512)
64. Choi J. Imaging of hepatic metastases. Cancer Control. 2006;13:6-12. (Pubitemid 43327549)
65. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. J Nucl Med. 2012;53:371-377.
66. 18F-FDG PET/ CT and Gd-EOB-DTPA-enhanced MRI. J Nucl Med. 2010;51:692-699.
67. Schreiter NF, Nogami M, Steffen I, et al. Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours. Eur Radiol. 2012;22:458-467.
68. 111In-DTPAOC (OctreoScan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617-1626.
69. Kam MH, Wong DC, Siu S, Stevenson AR, Lai J, Phillips GE. Comparison of magnetic resonance imaging-fluorodeoxy-glucose positron emission tomography fusion with pathological staging in rectal cancer. Br J Surg. 2010;97:266-268.
70. Al-Sukhni E, Milot L, Fruitman M, et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol. January 20, 2012 [Epub ahead of print].
71. Muthusamy VR, Chang KJ. Optimal methods for staging rectal cancer. Clin Cancer Res. 2007;13:6877s-6884s.
72. Grassetto G, Marzola MC, Minicozzi A, Al-Nahhas A, Rubello D. F-18 FDG PET/CT in rectal carcinoma: where are we now? Clin Nucl Med. 2011;36:884-888.
73. 18F-FDGPET/CT. J Comput Assist Tomogr. 2011;35:531-534.
74. Wieder HA, Rosenberg R, Lordick F, et al. Rectal cancer: MR imaging before neoadjuvant chemotherapy and radiation therapy for prediction of tumor-free circumferential resection margins and long-term survival. Radiology. 2007;243:744-751. (Pubitemid 46799428)
75. Park MJ, Kim SH, Lee SJ, Jang KM, Rhim H. Locally advanced rectal cancer: added value of diffusion-weighted MR imaging for predicting tumor clearance of the mesorectal fascia after neoadjuvant chemotherapy and radiation therapy. Radiology. 2011;260:771-780.
76. Curvo-Semedo L, Lambregts DM, Maas M, Beets GL, Caseiro-Alves F, Beets-Tan RG. Diffusion-weighted MRI in rectal cancer: apparent diffusion coefficient as a potential noninvasive marker of tumor aggressiveness. J Magn Reson Imaging. January 23, 2012 [Epub ahead of print].
77. Lambregts DM, Cappendijk VC, Maas M, Beets GL, Beets-Tan RG. Value of MRI and diffusion-weighted MRI for the diagnosis of locally recurrent rectal cancer. Eur Radiol. 2011;21:1250-1258.
78. Vliegen RF, Beets GL, Lammering G, et al. Mesorectal fascia invasion after neoadjuvant chemotherapy and radiation therapy for locally advanced rectal cancer: accuracy of MR imaging for prediction. Radiology. 2008;246:454-462.
79. Vliegen RF, Beets-Tan RG, Vanhauten B, et al. Can an FDG-PET/CT predict tumor clearance of the mesorectal fascia after preoperative chemoradiation of locally advanced rectal cancer? Strahlenther Onkol. 2008;184:457-464.
80. Moore HG, Akhurst T, Larson SM, Minsky BD, Mazumdar M, Guillem JG. A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. J Am Coll Surg. 2003;197:22-28. (Pubitemid 36759175)